archive-au.com » AU » C » CSL.COM.AU

Total: 502

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Recording of Analyst Briefing
    with CSL Managing Director and Chief Executive Officer Dr Brian McNamee This was recorded on May 28th 2009 following CSL s response to the FTC announcement regarding CSL Limited s acquisition of Talecris CSL Limited responds to FTC announcement Listen Now This recording is approximately one hour long and can be listened to stopped and restarted using the controls below Please click to activate the controls Media Contacts Australia Dr

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650230/news/1242703935711/prdetail.htm (2014-01-05)
    Open archived version from archive


  • CSL Limited responds to FTC announcement
    Responsibility Careers Newsroom Contact CSL Home Archived ASX Releases CSL Limited responds to FTC announcement CSL Limited responds to FTC announcement Melbourne Australia 28 05 2009 CSL Limited ASX CSL today was informed that the US Federal Trade Commission FTC will file a complaint in the US Federal District Court to challenge CSL s proposed acquisition of Talecris Biotherapeutics Dr Brian McNamee CEO and Managing Director of CSL Limited said We strongly disagree with the FTC s decision to challenge the deal CSL intends to vigorously oppose the FTC s actions The FTC has failed to recognize that this combination is pro competitive provides significant efficiencies that will improve the supply of biotherapies and is beneficial to the patient community The Commission failed to take into account the substantial remedies that were offered by CSL which addressed their concerns especially in relation to plasma supply Alpha 1 and RhoD Download this release CSL Limited responds to FTC announcement 0 89 MB Analyst Briefing Listen to the recording made during the analyst briefing Media Contacts Australia Dr Rachel David Director Public Affairs CSL Limited Telephone 613 9389 1821 Email rachel david csl com au Tim Duncan Hinton Associates Telephone 613 9600

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650230/news/1242703908232/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Archived ASX Releases
    US Federal Trade Commissioners regarding Talecris Acquisition CSL meets with US Federal Trade Commissioners regarding Talecris Acquisition Melbourne Australia 25 05 2009 CSL Limited today announced that Managing Director Dr Brian McNamee met with U S Federal Trade Commission FTC Commissioners in Washington DC on 22 May to discuss CSL s proposed acquisition of Talecris Biotherapeutics Inc Download this release CSL meets with US Federal Commissioners regarding Talecris Acquisition 0

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650230/news/1242703870345/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Archived ASX Releases
    Biotherapeutics Market Speculation Melbourne Australia 07 05 2009 CSL Limited has become aware of market and media speculation regarding the proposed acquisition of Talecris Biotherapeutics Inc This matter is currently being considered by the U S Federal Trade Commission FTC including the potential for remedies This development is not unusual and provides no indication that the deal will or will not proceed or the timing of an FTC decision CSL

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650230/news/1241397150314/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Archived ASX Releases
    CSL Plasma Germany About CSL Our Businesses Our Products Research and Development Business Development Investors Corporate Responsibility Careers Newsroom Contact CSL Home Archived ASX Releases CSL Half year Results Announcement for 2008 09 CSL Half year Results Announcement for 2008 09 Melbourne Australia 18 02 2009 CSL Limited today announced its first half result for period ended 31 December 2008 Download this release CSL Half year Results Announcement for 2008

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650230/news/1234772848181/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Archived ASX Releases
    UK USA CSL Plasma US CSL Plasma Germany About CSL Our Businesses Our Products Research and Development Business Development Investors Corporate Responsibility Careers Newsroom Contact CSL Home Archived ASX Releases CSL Limited Change of Company Secretary CSL Limited Change of Company Secretary Melbourne Australia 16 01 2009 With immediate effect Mr Edward Bailey is the company secretary of CSL Limited Mr Peter Turvey will continue as assistant company secretary in

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650230/news/1229961374317/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Archived ASX Releases
    Releases CSL Receives FTC Request for Additional Information CSL Receives FTC Request for Additional Information Melbourne Australia 13 10 2008 CSL Receives FTC Request for Additional Information on its Proposed Merger with Talecris Biotherapeutics CSL Limited today announced that it has received a request for additional information commonly referred to as a Second Request from the U S Federal Trade Commission FTC regarding its proposed acquisition of Talecris Biotherapeutics which

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650230/news/1221487209028/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Archived ASX Releases
    Australia 02 09 2008 CSL today announced that Mr David Anstice has been appointed a Director of the Company effective 2 September 2008 Mr Anstice was a senior executive of Merck Co Inc for many years retiring as 1 September 2008 Mr Anstice served as President of Merck Human Health for the US Canada Europe Japan and Asia in separate assignment He has also been responsible for Merck s prescription

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650230/news/1219872134045/prdetail.htm (2014-01-05)
    Open archived version from archive